<p>Multiple myeloma (MM) is still an incurable hematological malignancy. Despite recent progress due to new anti-myeloma agents, the pathology is characterized by a high frequency of <i>de novo</i> or acquired resistance. Delineating the mechanisms of MM resistance is essential for therapeutic advances. We previously showed that long-term genotoxic stress induces the establishment of a senescence-associated secretory phenotype, a pro-inflammatory response that favors the emergence of cells with cancer stem-like properties. Here, we studied the short-term response of MM cells following treatment with various DNA damaging agents such as the energetic C-ion irradiation. MM cells are highly resistant to all treatments and do not enter apoptosis...
Multiple myeloma (MM) is a blood cancer characterised by the uncontrolled proliferation and dissemin...
DNA damage is deleterious to all cells, but especially to stem cells because they maintain tissue in...
PETHEMA/GEM Cooperative Group.Patients with multiple myeloma (MM) carrying standard- or high-risk cy...
International audienceMultiple myeloma (MM) is still an incurable hematological malignancy. Despite ...
Despite recent advancements in therapy, multiple myeloma (MM) remains incurable. While the reasons f...
Multiple Myeloma (MM) is a genetically complex and heterogeneous hematological cancer that remains i...
Human myeloma cell lines (HMCLs) and a subset of myeloma patients with poor prognosis exhibit high l...
UnlabelledMultiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although t...
Genotoxic stress can promote antitumor NK cell responses by upregulating the surface expression of a...
The increasing importance of hypoxia-inducible factor-1α (HIF-1α) in tumorigenesis raises the possib...
This thesis is focused on multiple myeloma (MM), a haematological malignancy that still remains incu...
Increasing evidence indicates that cancer cell stress induced by chemotherapeutic agents promote ant...
Multiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although the mechani...
The era of targeted therapies has seen significant improvements in depth of response, progression-fr...
International audienceAdult stem cells including multipotent mesenchymal stromal cells (MSC) acquire...
Multiple myeloma (MM) is a blood cancer characterised by the uncontrolled proliferation and dissemin...
DNA damage is deleterious to all cells, but especially to stem cells because they maintain tissue in...
PETHEMA/GEM Cooperative Group.Patients with multiple myeloma (MM) carrying standard- or high-risk cy...
International audienceMultiple myeloma (MM) is still an incurable hematological malignancy. Despite ...
Despite recent advancements in therapy, multiple myeloma (MM) remains incurable. While the reasons f...
Multiple Myeloma (MM) is a genetically complex and heterogeneous hematological cancer that remains i...
Human myeloma cell lines (HMCLs) and a subset of myeloma patients with poor prognosis exhibit high l...
UnlabelledMultiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although t...
Genotoxic stress can promote antitumor NK cell responses by upregulating the surface expression of a...
The increasing importance of hypoxia-inducible factor-1α (HIF-1α) in tumorigenesis raises the possib...
This thesis is focused on multiple myeloma (MM), a haematological malignancy that still remains incu...
Increasing evidence indicates that cancer cell stress induced by chemotherapeutic agents promote ant...
Multiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although the mechani...
The era of targeted therapies has seen significant improvements in depth of response, progression-fr...
International audienceAdult stem cells including multipotent mesenchymal stromal cells (MSC) acquire...
Multiple myeloma (MM) is a blood cancer characterised by the uncontrolled proliferation and dissemin...
DNA damage is deleterious to all cells, but especially to stem cells because they maintain tissue in...
PETHEMA/GEM Cooperative Group.Patients with multiple myeloma (MM) carrying standard- or high-risk cy...